Welcome to Beauty In A Tik, where each week we put TikTok’s viral beauty hacks and innovative trends to the test.

Demi Lovato has opened up about the lasting health struggles she continues to face following her 2018 overdose. The “Sorry Not Sorry” singer recently appeared on SiriusXM’s Andy Cohen Live, where she revealed that her near-fatal overdose left her with vision and hearing impairment. “I wouldn’t change my path because I don’t have any regrets,” she told host Andy Cohen on Wednesday 12 July. “The closest thing that I get to a regret is when I overdosed and I wish somebody had told me, one, that I was beautiful, because I didn’t believe it,” Lovato shared. “And two, I wish that someone would’ve told me that if you just sit with the pain, it passes.” “That overdose caused me a lot of - it actually caused a disability. I have vision impairment and hearing impairment to this day,” the 30-year-old singer said, even admitting that she doesn’t drive anymore due to “blind spots in [her] vision”. However, the Disney Channel alum went on to explain how the lasting effects of her overdose are a “daily constant reminder” throughout her sobriety journey. “Anytime I look at something - like, I have blind spots in my vision when I look at your face,” Lovato told Cohen. “And so it’s a constant reminder to stay on the right path, because I never want that to happen again.” In July 2018, Demi Lovato was rushed to the hospital after suffering “complications” from a reported overdose. She had previously celebrated six years of being sober. In her YouTube documentary series, Dancing with the Devil, which was released in March 2021, Lovato revealed that she became addicted to meth, heroin, and crack cocaine in the weeks before her overdose. “I’m surprised I didn’t OD that night,” she shared in the docuseries. “I just went to town. I went on a shopping spree. That night I did drugs I’d never done before. I’d never done meth before, I tried meth. I mixed it with [ecstasy], with coke, weed, alcohol, oxycontin. And that alone should have killed me.” Two weeks later, she added, she was “introduced to heroin and crack cocaine”. Lovato suffered three strokes and a heart attack during her overdose, leaving her with permanent brain damage. Lovato has been very open about her sobriety journey and mental health struggles. When the “Skyscraper” singer was diagnosed with bipolar disorder in 2011, Lovato shared that the diagnosis provided her with a sense of “relief” because she had spent “so many years struggling” with her mental health. “I was so relieved that I had finally had a diagnosis,” Lovato said at the Hollywood & Mind Summit in Los Angeles last May. “I had spent so many years struggling, and I didn’t know why I was a certain way in dealing with depression at such extreme lows, when I seemingly had the world in front of me just ripe with opportunities.” Lovato is now fully sober after initially adopting a “California sober” approach that involved marijuana and alcohol in moderation. “I no longer support my ‘California sober’ ways,” the singer said in an Instagram Story in December 2021. “Sober sober is the only way to be.” Read More Demi Lovato changed pronouns because explaining They/Them to people was ‘absolutely exhausting’ Demi Lovato explains why she was ‘relieved’ to be diagnosed with bipolar disorder Demi Lovato reveals she used opiates for first time at 13 Marina Diamandis says she has been diagnosed with chronic fatigue syndrome Should I keep my windows closed or open during a heatwave? How to sleep during hot weather, according to experts

CBS' latest game show, “Superfan,” premiering Wednesday, gathers one musical act and their fans each week into a studio and gradually whittles the contestants down to two, giving online voters the final say on who will be crowned the ultimate superfan

TORONTO--(BUSINESS WIRE)--Sep 7, 2023--

Using MRI scans to screen men for prostate cancer could reduce deaths from the disease “significantly”, researchers have suggested. Scientists said current tests, which detect the level of the protein prostate-specific antigen (PSA) in the blood, have been linked to over-diagnosis and over-treatment of low-risk cancer. Prostate cancer is the most common cancer found in men and, at the moment, those aged over 50 can request a PSA test if they are experiencing symptoms. The Reimagine study invited 303 men aged between 50 and 75 to have a screening MRI and a PSA test. Of the total, 48 (16 per cent) had an MRI that indicated the presence of prostate cancer despite having a median PSA density. Of the group, 32 had lower PSA levels than the current screening benchmark of 3ng/ml, meaning they would not have been referred for further investigation. After NHS assessment, 29 men were diagnosed with cancer that required treatment, 15 of whom had serious cancer and a PSA of less than 3ng/ml. Three men (1 per cent) were diagnosed with low-risk cancer that did not require treatment. Our results give an early indication that MRI could offer a more reliable method of detecting potentially serious cancers early Prof Caroline Moore The study was led by University College London, University College London Hospitals NHS Foundation Trust and King’s College London and is published in medical journal BMJ Oncology. Prof Caroline Moore, consultant surgeon at UCLH, chief investigator of the study and NIHR research professor, said the findings are “sobering” and “reiterates the need to consider a new approach to prostate cancer screening”. “Our results give an early indication that MRI could offer a more reliable method of detecting potentially serious cancers early, with the added benefit that less than 1 per cent of participants were ‘over-diagnosed’ with low-risk disease,” she added. Prof Mark Emberton, consultant urologist at UCLH, said: “The UK prostate cancer mortality rate is twice as high as in countries like the US or Spain because our levels of testing are much lower than other countries. “Given how treatable prostate cancer is when caught early, I’m confident that a national screening programme will reduce the UK’s prostate cancer mortality rate significantly. There is a lot of work to be done to get us to that point, but I believe this will be possible within the next five to ten years.” Nick James, a professor of prostate and bladder cancer research at the Institute of Cancer Research in London said the study “further reinforces the value of MRI in the diagnostic pathway for prostate cancer”. “The well-known limitations of the old PSA-based screening studies of over- diagnosis and linked over-treatment are increasingly mitigated by the use of MRI,” he added. “Similarly, MRI can also spot cases of prostate cancer in patients with normal PSA levels, who would have been missed using PSA only screening programmes.” MRI scans have revolutionised the way we diagnose prostate cancer, and it’s great to see research into how we might use these scans even more effectively Simon Grieveson, Prostate Cancer UK Prof Sir Mike Richards, chairman of the UK National Screening Committee (NSC), said the organisation does not currently recommend prostate cancer screening “because there is no clear evidence that the benefits outweigh the harms”. However, it is preparing to look at various proposals. He added: “The UK NSC will soon commission a major piece of work to consider six prostate cancer screening proposals that were submitted during its annual call for topics. “These include targeted and risk-stratified screening proposals for screening groups of men at higher risk due to factors such as ethnicity and family history.” Simon Grieveson, assistant director of research at Prostate Cancer UK, said: “MRI scans have revolutionised the way we diagnose prostate cancer, and it’s great to see research into how we might use these scans even more effectively. “These results are extremely exciting, and we now want to see much larger, UK-wide studies to understand if using MRI as the first step in getting tested could form the basis of a national screening programme.” Another trial, known as Limit, is being conducted with a much larger number of patients, which the research team said is the “next step towards a national prostate screening programme”. The trial will also attempt to recruit more black men, after the team behind Reimagine found they were much less likely to respond to the invitation to screening than others. Saran Green of King’s College London said: “One in four black men will get prostate cancer during their lifetime, which is double the number of men from other ethnicities. “Given this elevated risk, and the fact that black men were five times less likely to sign up for the Reimagine trial than white men, it will be crucial that any national screening programme includes strategies to reach black men and encourage more of them to come forward for testing.”

Pamela Anderson has explained she wanted to "challenge beauty" by going make-up free in public.

Utah-based content creator Serena Neel bought her first-ever designer handbag in May. To mark the occasion, she chose a Louis Vuitton Neverfull, the signature tote that’s been a part of the house’s heritage offerings since it was first introduced in 2007. “It’s always been my absolute favorite bag,” says Neel.

At PCMag, we like to see identity theft protection paired with a powerful device-level security

In October 2021, Agnes Tirop was found lying in a pool of blood in her modest bungalow in

The $149 Verizon Gizmo Watch 3, a GPS-tracking smartwatch for kids ages 3 to 11,

If you're looking to binge The Gilded Age or do a Thanksgiving rewatch of The

CITY OF INDUSTRY, Calif.--(BUSINESS WIRE)--Jun 8, 2023--